Ginkgo Bioworks Holdings, Inc. (DNA)

SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 22, 2026

Verified against EDGAR
Total Assets
$990.0M
Stockholders' Equity
$420.3M
Cash & Equivalents
$84.5M
Long-Term Debt
—

as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Jun 30, 2026, Ginkgo Bioworks Holdings, Inc. reported revenue of $20.2M, net income of -$46.7M, and total assets of $990.0M. Every figure below is taken directly from Ginkgo Bioworks Holdings, Inc.'s SEC filings: each links to the source document on EDGAR.

Revenue trend

Revenue · FY2019–FY2025 · as reported

$477.7M-$813.6M-$2.10B
FY2019FY2021FY2023FY2025
Revenue$170.2MNet income-$312.8M
FY2019 revenue
$54.2M
FY2025 revenue
$170.2M

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025$170.2M-$312.8M
FY2024$227.0M-$547.0M
FY2023$251.5M-$892.9M
FY2022$477.7M-$2.10B
FY2021$313.8M-$1.83B
FY2020$76.7M-$126.6M
FY2019$54.2M-$119.3M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KOct 29, 2026on EDGAR ↗
10-QAug 6, 2026on EDGAR ↗
8-KAug 5, 2026on EDGAR ↗
8-KJul 30, 2026on EDGAR ↗
8-KJun 12, 2026on EDGAR ↗
8-KMay 7, 2026on EDGAR ↗
10-QMay 7, 2026on EDGAR ↗
DEF 14AApr 29, 2026on EDGAR ↗
8-KApr 7, 2026on EDGAR ↗
8-KFeb 27, 2026on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Jun 30, 2026 · 10-Q

Total Assets$990.0Msource ↗
Stockholders’ Equity$420.3Msource ↗
Cash & Equivalents$84.5Msource ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Jun 30, 2026

Revenue$20.2Msource ↗
Net Income-$46.7Msource ↗
Operating Income-$58.5Msource ↗
Gross Profit$18.4Msource ↗
Cost of Revenue$1.7Msource ↗
R&D Expense$46.2Msource ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Jun 30, 2026

EPS (diluted)—source ↗
EPS (basic)$-0.75source ↗
Shares Outstanding63.7Msource ↗
Cash from Operations-$44.3Msource ↗
Cash from Financing$16.5Msource ↗
Cash from Investing$11.1Msource ↗

Insider activity

Form 4 open-market activity, last 180 days

Buys
0
Sells
11
Net shares
-137.6K

Restatement history

Point-in-time

No material restatements detected across 195 annual fact-keys: this company's as-filed numbers have held between filings. Point-in-time and as-of history are available via the API.

Deeper fundamentals

A free API key reaches DNA’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/DNA

MCP tool: get_sec_fundamentals ticker=DNA

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/DNA/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=DNA as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/DNA/history

MCP tool: get_fundamentals_history ticker=DNA

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/financial-health/DNA

MCP tool: get_financial_health ticker=DNA

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.